Simplify Logo

Full-Time

Senior Director

Pharmacology & DMPK

Posted on 6/6/2024

Prime Medicine

Prime Medicine

201-500 employees

Gene editing technology for genetic diseases

Hardware
Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree such as M.S. or Ph.D. in biological sciences
  • 10+ years of relevant experience in toxicology, pharmacology, or related discipline
  • Experience designing PK/PD studies including large animal studies
  • Experience building and managing collaborations with CROs, consultants, pharmaceutical partners, and other organizations
  • Ability to manage multiple therapeutic programs in parallel
  • Strong appreciation for research with a focus on product development and preclinical studies
  • Proven track record of strategic thinking and tactical implementation
  • Comfortable in an entrepreneurial and fast-paced environment
Responsibilities
  • Lead Pharmacology, BA, and DMPK groups
  • Design, execute, analyze, and interpret pharmacology, PK/PD, mechanistic, and safety studies
  • Maintain an effective network of outside partners and collaborators
  • Provide support to Tech Ops for real-time issues with drug substance/drug product
  • Ensure high-quality review of study documents and represent Pharmacology during interactions with Regulatory Agencies
  • Foster transparency of progress against department goals and manage conflicting priorities
  • Provide guidance on potential business development opportunities

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, Prime Medicine collaborates with research institutions and pharmaceutical companies to advance its technology and generate revenue through licensing and partnerships. The leadership team, including experienced professionals like Chief Technical Officer Ann L. Lee, is dedicated to enhancing the company's technological capabilities and expanding operations.

Company Stage

N/A

Total Funding

$596M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

1%

1 year growth

2%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $161 million PIPE offering and previous substantial funding rounds indicate strong investor confidence and financial stability.
  • Partnerships with organizations like the Cystic Fibrosis Foundation provide both financial support and validation of Prime Medicine's technology.
  • Successful preclinical data in non-human primates demonstrate the potential efficacy and safety of Prime Editing, bolstering the company's scientific credibility.

What critics are saying

  • The highly competitive biotech landscape requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and the complexity of clinical trials could delay the commercialization of Prime Editing therapies.

What makes Prime Medicine unique

  • Prime Medicine's Prime Editing technology offers unparalleled precision in DNA modification, setting it apart from other gene-editing techniques like CRISPR.
  • The company's focus on developing one-time curative therapies for genetic diseases provides a unique value proposition in the biotech sector.
  • Strategic collaborations with research institutions and pharmaceutical companies enhance Prime Medicine's ability to innovate and bring its technology to market.
INACTIVE